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In our medicinal organic chemistry research lab, I am performing a ninhydrin-based enzyme inhibition assay, previously developed in our lab, to discover novel antibiotics to combat antibiotic resistance that poses an imminent public 
health crisis. These drugs target the bacterial enzyme N-succinyl-L,L-diaminopimelic acid desuccinylase (DapE), a crucial enzyme to bacterial survival due to its involvement in the biosynthetic pathway of lysine, an amino acid essential 
to protein synthesis and mDAP, which is essential for bacterial cell wall construction. This pathway is exclusive to bacteria and is not found in mammalian cells, thus inhibition of this enzyme should be selectively toxic to bacteria. The 
assay enables testing of potential new inhibitors of DapE, done by spectrophotometric analysis of the products of the in vitro enzyme assay, quantitatively analyzing the amount of enzyme substrate converted to product. The goal is to 
evaluate several newly discovered inhibitor series involving indoline sulfonamides, tetrazoles, and N-aryl sulfonamides. Studying analogs of these compounds will greatly aid our understanding of the enzyme dynamics involved in the 
inhibition process. This information will broaden our understanding of the enzyme’s catalytic machinery to significantly aid in our future endeavors of drug synthesis and drug discovery for the optimization of new inhibitors.
Objectives
To work in collaboration with graduate students as well as 
undergraduate students within Dr. Becker’s research group who are 
synthesizing compounds that require testing in the assay to obtain 
their inhibitory potency against DapE.
Through the utilization of the computational suite, the Molecular 
Operating Environment (MOE), and a High Throughput Screen (HiTS), 
we discovered several potential new inhibitor series for DapE, which 
include indoline sulfonamides4, tetrazoles, and N-aryl sulfonamides. 
Our group has also designed cyclobutanones as DapE inhibitors.5
After hypothesizing that these molecules would inhibit DapE, analogs 
of the original hits were either previously synthesized or continue to 
be synthesized, and then, each of these compounds must be assessed 
in the assay to obtain inhibition data.
Once the inhibition data is obtained, the molecular interactions 
between DapE’s structure and the potential inhibitors may be 
analyzed to provide greater understanding of the enzyme dynamics 
involved in the inhibition process. This greater understanding will 
significantly aid in future endeavors of drug synthesis and drug 
discovery for the optimization of new inhibitors.
Methodology
In order to demonstrate inhibition of DapE to test potential antibiotic efficacy, the biochemical 
assay developed in our research group3 is utilized. This consists of the incubation of the active 
DapE enzyme, a modified substrate, N-methylsuccinyl diaminopimelic acid (N-Me-SDAP), HEPES 
buffer, and the inhibitor. In addition, the potential inhibitors are tested at various concentrations at 
30℃ for 10 minutes, then the reaction is quenched by heating for 1 minute to deactivate the 
enzyme. Then, ninhydrin is added, which reacts with the primary amine of the now-cleaved 
product, converting the solution to a shade of purple. The absorbance at 570 nm is then measured 
in a spectrophotometer through the utilization of a well-plate reader, and different absorbance 
values are obtained, which represent the amount of substrate converted to product within the 
assay. After subtracting background absorbance, the inhibition for each concentration of inhibitor 
is calculated. After running the assay in triplicate, using 100% enzymatic activity, 0% enzymatic 
activity, and glutamic acid controls, the IC50 of each potential inhibitor can be accurately obtained.
3 
Within medicinal chemistry and drug discovery, the IC50 refers to half the maximum inhibitory 
concentration, and it is utilized to compare the effect that potential drugs have on specific 
biological pathways or processes. It is one of the most common ways to report inhibitory effects of 
small molecule drug candidates. Now, with this inhibition data, the synthesized compounds may be 
compared with previously identified DapE inhibitors, such as the thiol-containing ACE inhibitor 
captopril, to determine their efficacy as potential new antibiotics. In addition, these data facilitate 
an understanding of the structure-activity relationships (SAR) between our synthesized compounds 
and the enzyme and enable us to iteratively improve our analogs.
Lead Molecules as DapE Inhibitors
Figure 1 contains the lead structure from each inhibitor series to demonstrate the wide variety of inhibitors 
being tested in our critical assay. Some lead molecules are in their beginning stages of synthesis, while the 
Becker group has just published advanced inhibitors based on the indolines 1 and 2.4
Figure 1. Lead molecules as DapE inhibitors
Continued Work
In addition, updates and improvements have been 
made for streamlining our assay to enable faster 
throughput and more accurate results. We are now 
utilizing a thermal cycler, an instrument that 
automatically regulates the temperature of the sample 
and the incubation time for each of those temperatures, 
all possible through programming. With the reduction of 
error, every IC50 value calculated utilizing the thermal 
cycler will be that much more accurate. This will greatly 
impact every single project in our research lab.
Additionally, it is imperative to note our ongoing work to 
broaden the scope of our research to combat growing 
antibiotic resistance. Therefore, in the future, we will be 
moving to set up the assay with the DapE enzyme from 
different bacterial species to confirm broad spectrum 
antibiotic activity. We are working in collaboration with 
CSGID (Center for Structural Genomics of Infectious 
Diseases) at Northwestern, as well as Argonne National 
Laboratories, to expand the validation of DapE as a target 
for different types of bacterial infections.
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Results and Conclusions
Inhibition data for a series of indolines has recently published by our group.4 We have obtained 
preliminary inhibition data for series 3 and 4 inhibitors, as well as for cyclobutanones, and this data will 
be published in due course. Furthermore, after performing these reactions and obtaining DapE inhibition 
data, we will co-crystallize the drug candidates in collaboration with Argonne National Laboratories and 
obtain high-resolution co-crystal structures of the inhibitors with the DapE enzyme to elucidate the 
binding mode of the inhibitors as well as the distinct enzyme conformations6 with the different 
compound moieties bound to the active sites. With this information, we will be able to advance our 
understanding of the enzyme-drug interactions through an improved knowledge of the structure activity 
relationship (SAR) between the different classes of inhibitors with the enzyme, which will in turn 
enhance our effort toward the discovery of new antibiotics.
Background
Although the world currently faces a major battle against the 
global COVID-19 pandemic, a longer-term ongoing fight continues 
against an increase in antibiotic resistant bacteria, underscoring 
the urgent need to discover antibiotics with a new mechanism of 
action.1 The Becker research group is addressing this increase in 
mortality and morbidity in order to advance our fight against 
antibiotic resistance. Our medicinal chemistry research has 
revealed the possibility of an entirely new class of antibiotics,
which targets a previously-unexplored biochemical pathway, 
Utilizing inhibition of the enzymatic activity 
of N-succinyl-L,L-diaminopimelic acid 
desuccinylase, or DapE (inset). 2 This enzyme 
is part of a crucial biosynthetic pathway that 
produces the amino acid lysine and mDAP, 
both essential to protein synthesis and 
bacterial peptidoglycan cell wall 
construction, respectively. Therefore, 
inhibition of DapE enzymatic activity is very 
attractive because its inhibition should be 
selectively lethal to bacteria, while safe for 
humans, as we receive lysine from our diet, 
and we do not express the DapE enzyme.
